Written and maintained by CASRAI Editorial Board
Last updated
CDA-AMC — Canada’s Drug Agency, known until May 1, 2024 as CADTH (the Canadian Agency for Drugs and Technologies in Health) — is the pan-Canadian body that decides whether a drug already authorized for sale by Health Canada is worth what it costs. That distinction trips up a lot of first-time searchers: CDA-AMC is not Canada’s equivalent of the US FDA. Health Canada plays that role, reviewing a drug’s safety, efficacy, and quality through the Clinical Trial Application and New Drug Submission process. CDA-AMC’s job starts after that authorization exists: it runs the health technology assessment (HTA) that most of Canada’s public drug plans use to decide what to actually pay for.
From CCOHTA to CADTH to CDA-AMC
The organization has changed its name twice. It was created in 1989 as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA), a federal response to provinces independently duplicating the same drug-assessment work. In 2006 it became CADTH, the name most Canadian research administrators and pharma-market-access professionals still default to. On May 1, 2024, CADTH completed a transition — managed through a federal Canadian Drug Agency Transition Office (CDATO) established in 2021, with $89.5 million in federal funding committed over five years — into Canada’s Drug Agency, branded CDA-AMC (the French acronym, Agence des médicaments du Canada, is built into the name itself). The rebrand isn’t just cosmetic: it signals an expanding federal mandate, explicitly framed as an early step toward a national pharmacare program, on top of the reimbursement-review function CADTH already performed.
Because the rename is recent, expect a mix of both names in the wild for a while yet: CADTH’s old domain (cadth.ca) now redirects to cda-amc.ca, and most professional literature and guidance documents published before 2024 will still say CADTH.
What CDA-AMC actually reviews
CDA-AMC’s reimbursement review is a comparative-value assessment, not a safety review. Once a manufacturer has (or is close to having) Health Canada market authorization, it can file a submission with CDA-AMC. An independent evidence review examines the clinical trial data plus the manufacturer’s cost-effectiveness model — whether the drug’s clinical benefit justifies its price relative to existing treatment options — and the review culminates in a public recommendation: reimburse, reimburse with clinical criteria or conditions, or do not reimburse.
Until the 2024 rebrand, this ran as two separate, differently-branded review streams: the Common Drug Review (CDR) for non-oncology drugs, and pCODR (the pan-Canadian Oncology Drug Review) for cancer drugs, each with its own recommendation committee. Both names are now retired in favour of a single, unified CDA-AMC reimbursement review process — if you’re reading older guidance documents or literature that still refers to “pCODR” or “the Common Drug Review,” that’s the pre-2024 structure, not a currently separate pathway.
A recommendation is not a listing decision
This is the step that most often gets misunderstood. CDA-AMC’s recommendation is advisory — it does not itself put a drug on any provincial formulary or determine what a public drug plan pays. Two more steps sit between a positive recommendation and an actual patient being able to access the drug through public coverage:
- Price negotiation. The pan-Canadian Pharmaceutical Alliance (pCPA) — a separate body representing participating federal, provincial, and territorial drug plans collectively — negotiates a confidential price with the manufacturer on behalf of those plans. CDA-AMC’s economic model informs this negotiation but doesn’t set the final price.
- Individual formulary listing. Each participating jurisdiction still makes its own final decision about whether, and under what conditions, to list the drug on its own public drug plan, after a pCPA agreement is reached. A positive CDA-AMC recommendation and a completed pCPA negotiation make listing likely, not automatic or simultaneous across every province.
Quebec adds a further wrinkle: it runs its own provincial HTA body, INESSS (Institut national d’excellence en santé et en services sociaux), which conducts its own assessment for Quebec’s public plan rather than relying solely on the CDA-AMC recommendation used by the rest of the country.
How CDA-AMC compares to NICE
CDA-AMC is Canada’s rough structural counterpart to the UK’s NICE and its technology appraisal process — both are the reference HTA body a manufacturer, health economist, or research administrator has to understand to get a drug reimbursed, and both weigh cost-effectiveness evidence including QALYs and an ICER against a threshold. The structural difference is consequential: NICE’s technology appraisal guidance for NHS-funded medicines in England carries a statutory funding direction — the NHS is legally required to fund what NICE recommends, on a set timeline, because there is a single payer. CDA-AMC has no equivalent binding authority over Canada’s fragmented, multi-payer system of federal, provincial, and territorial drug plans; its recommendation is one input that pCPA negotiation and individual jurisdictions still have to act on separately, which is exactly why the pCPA-negotiation and per-jurisdiction-listing steps above exist and NICE has no equivalent of either.
Where this fits in the Canadian drug-to-patient pathway
For a sponsor or research administrator tracking a product from first-in-human trial to public reimbursement in Canada, CDA-AMC’s review is one stage in a longer sequence: a Clinical Trial Application and Research Ethics Board approval authorize the trial itself; a Notice of Compliance from Health Canada authorizes the drug for sale; a CDA-AMC reimbursement review then assesses whether public drug plans should pay for it; pCPA negotiates the price; and individual provinces and territories make the final listing call. Each stage is run by a different body with a different question to answer — conflating “Health Canada approved it” with “it’s covered” is a common and consequential mistake for anyone new to the Canadian system.
Frequently asked questions
Is CDA-AMC the same as Health Canada? No. Health Canada is the regulator that authorizes a drug for sale based on safety, efficacy, and quality. CDA-AMC is a separate, arm’s-length organization that reviews already-authorized drugs for cost-effectiveness and informs public-plan reimbursement decisions. A drug can be fully approved by Health Canada and still not be reimbursed by any public drug plan.
What does CDA-AMC stand for? Canada’s Drug Agency — Agence des médicaments du Canada. The bilingual acronym is built into the brand itself rather than translated separately.
Is CADTH still a real organization? Not as a separate entity as of May 1, 2024 — CADTH transitioned into CDA-AMC, keeping the same core reimbursement-review function under a new name and an expanded federal mandate. cadth.ca now redirects to cda-amc.ca.
Does a CDA-AMC recommendation guarantee provincial coverage? No. It’s advisory. Coverage depends on a subsequent pCPA price negotiation and each province or territory’s own separate listing decision, and Quebec runs a parallel process through INESSS rather than relying on the CDA-AMC recommendation alone.
